Telix Pharmaceuticals Ltd. has announced the successful production and delivery of its first Good Manufacturing Practice $(GMP.UK)$-grade commercial radiopharmaceutical doses from its Telix Manufacturing Solutions facility in Brussels South, Belgium. This milestone marks the expansion of Telix's commercial radiopharmacy capabilities in Europe. The facility, which is one of the largest in Europe, features nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons. This advancement allows Telix to provide GMP-grade products and radiolabelling services, enhancing access to radiopharmaceuticals in Belgium and beyond. The move is expected to significantly impact patient care, particularly in cancer treatment, while supporting future production of important isotopes and radiopharmaceuticals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。